What is Zacks Research’s Forecast for IRWD FY2026 Earnings?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Zacks Research lowered their FY2026 EPS estimates for shares of Ironwood Pharmaceuticals in a research note issued on Tuesday, December 10th. Zacks Research analyst R. Department now forecasts that the biotechnology company will post earnings of $0.43 per share for the year, down from their prior estimate of $0.44. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.08 per share.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Thursday, November 7th. The biotechnology company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The firm had revenue of $91.60 million for the quarter, compared to the consensus estimate of $91.22 million. During the same quarter in the previous year, the business posted $0.12 EPS. Ironwood Pharmaceuticals’s revenue was down 19.4% on a year-over-year basis.

IRWD has been the topic of a number of other research reports. StockNews.com lowered Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 12th. Leerink Partnrs raised Ironwood Pharmaceuticals to a “hold” rating in a report on Monday, September 9th. Finally, Leerink Partners began coverage on Ironwood Pharmaceuticals in a research report on Monday, September 9th. They issued a “market perform” rating and a $5.00 target price on the stock. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $10.40.

Ironwood Pharmaceuticals Price Performance

Shares of IRWD opened at $3.53 on Friday. The firm has a market cap of $564.91 million, a P/E ratio of -117.67 and a beta of 0.41. Ironwood Pharmaceuticals has a 1 year low of $3.06 and a 1 year high of $15.70. The company has a 50 day simple moving average of $4.03 and a two-hundred day simple moving average of $5.02.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. KBC Group NV increased its position in Ironwood Pharmaceuticals by 59.3% in the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 3,198 shares during the period. CWM LLC boosted its position in shares of Ironwood Pharmaceuticals by 55.1% in the 2nd quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 2,345 shares during the period. Wolverine Trading LLC purchased a new position in Ironwood Pharmaceuticals in the 3rd quarter worth about $51,000. Diversified Trust Co purchased a new stake in Ironwood Pharmaceuticals during the third quarter valued at about $52,000. Finally, Legacy Capital Group California Inc. purchased a new stake in Ironwood Pharmaceuticals during the third quarter valued at about $59,000.

Insiders Place Their Bets

In other Ironwood Pharmaceuticals news, CFO Sravan Kumar Emany sold 11,001 shares of the company’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $4.08, for a total value of $44,884.08. Following the sale, the chief financial officer now owns 309,572 shares of the company’s stock, valued at approximately $1,263,053.76. This represents a 3.43 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 12.90% of the stock is currently owned by corporate insiders.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.